Based at Salisbury South pharmaceutical company Mayne Pharma is investing $25 million in its manufacturing facility to support their significant export opportunities in the United States as highlighted by a story on AdelaideNow
Mayne Pharma is expanding by putting in new infrastructure and equipment in to its facility over the next 18 months.
Much of the spend is related to the production of its Doryx brand which is a treatment for acne in the US as Mayne last year suecured the marketing right for the brand in its biggest market.
Its expected this will fuel a growth in high-tech jobs which as already see a 25% growth in staff over the past two years to 200.
There will be high-tech jobs in the future at the site, which also houses its research and development centre, where the company innovates to improve older patents and formulations.
The Salisbury workforce has grown by 25 per cent in the past two years to 200 staff.
Their expansion plans includes
- $10 million is going towards equipment, including a fluid bed dryer and sprayers, to add polymers or coatings to the drug that can control its release in the body.
- $15 million is towards new tablet presses, high-sheer granulators and a tablet film coater which will be put into a new manufacturing rooms.
- 600 square metres of new processing areas within the existing (12,000sq m) factory
The production faculties at Salisbury makes about 3 billion capsules and tablets, 100 metric tonnes of bulk product and 16 million units of liquids and creams of which 75% is exported to US. Other markets also include South Korea, Canada and some parts of Europe and Asia.
In SA, Mayne Pharmaâ€™s history stems from FH Faulding and Co and the company remains one of the largest and most prominent public companies headquartered in South Australia.